Open

Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients With Soft Tissue Sarcoma

In this study, we want to find out if a combination of 3 different study drugs (Cabozantinib, Ipilimumab, and Nivolumab) will affect the progression of Soft Tissue Sarcoma.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

You will be randomized to a combination of drugs. You will receive the drugs via IV. You will receive treatment until disease progression. You will then be contacted 30 days after your last dose to evaluate any adverse events.

Incentives

Study Drug

In-person visits:
All

Total length of participation:
Until disease progression

Looking for Specific Volunteers

Able to participate:

Confirmed metastatic Sarcoma
Adequate Organ and Marrow function
Average blood pressure lower than 140/90

Not eligible if:

Are on another investigational trial
History of allergic reactions to the investigational drug
If you are pregnant

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clincal Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Mark Woodcock
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Sarcoma (bone and soft tissue))

IRB Number

24-0298

ClinicalTrials.gov

NCT05836571

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.